175 related articles for article (PubMed ID: 12798707)
1. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
Rose PG; Fusco N; Smrekar M; Mossbruger K; Rodriguez M
Gynecol Oncol; 2003 Jun; 89(3):429-33. PubMed ID: 12798707
[TBL] [Abstract][Full Text] [Related]
2. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
4. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
Pasternak AL; Link NA; Richardson CM; Rose PG
Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study.
Koul A; Forsland EL; Bjurberg M
Gynecol Oncol; 2018 Feb; 148(2):363-367. PubMed ID: 29208369
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M; Hsieh F; Zanotti K; Webster K; Peterson G; Kulp B; Spicel A; Belinson J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):25-8. PubMed ID: 14564516
[TBL] [Abstract][Full Text] [Related]
9. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
[TBL] [Abstract][Full Text] [Related]
10. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
[TBL] [Abstract][Full Text] [Related]
11. A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity.
McElroy TM; Gruenigen VE; Waggoner SE
Gynecol Oncol; 2003 Nov; 91(2):435-7. PubMed ID: 14599880
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
13. Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization.
Rose PG; Metz C; Link N
Int J Gynecol Cancer; 2014 Nov; 24(9):1603-6. PubMed ID: 25304679
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
15. Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin.
Chikazawa K; Netsu S; Imai K; Ishiguro A; Kimura A; Wang L; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2020 Jul; 59(4):546-550. PubMed ID: 32653127
[TBL] [Abstract][Full Text] [Related]
16. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin desensitization.
Choi J; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin desensitization.
Keat K; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):468-9. PubMed ID: 18051220
[No Abstract] [Full Text] [Related]
19. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
LaVigne K; Hyman DM; Zhou QC; Iasonos A; Tew WP; Aghajanian C; Makker V; Hensley ML; Konner J; Grisham RN; Cangemi N; Soldan K; Spriggs DR; Sabbatini PJ; OʼCearbhaill RE
Int J Gynecol Cancer; 2018 Jul; 28(6):1176-1182. PubMed ID: 29757876
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Escobar PF; Markman M; Rose P; Zanotti K; Webster K; Belinson J
Gynecol Oncol; 2004 Jan; 92(1):192-6. PubMed ID: 14751157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
